argenx Management
Management criteria checks 3/4
argenx's CEO is Tim Van Hauwermeiren, appointed in Apr 2008, has a tenure of 16.08 years. total yearly compensation is $11.94M, comprised of 5.5% salary and 94.5% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth $42.84M. The average tenure of the management team and the board of directors is 2.3 years and 7.1 years respectively.
Key information
Tim Van Hauwermeiren
Chief executive officer
US$11.9m
Total compensation
| CEO salary percentage | 5.5% |
| CEO tenure | 16.1yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2.3yrs |
| Board average tenure | 7.1yrs |
Recent management updates
Recent updates
argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion
Feb 01Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod
Sep 21Argenx's neuromuscular disorder drug Vyvgart wins approval in EU
Aug 11Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M
Jul 28argenx: A Very Good Start For Vyvgart
May 25argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain
May 18argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers
Mar 07argenx: Vyvgart's Approval A Key Step For Continued Value Creation
Dec 22argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers
Nov 30argenx: R&D Day Goes Unnoticed
Aug 23argenx: Next Phase Of Growth With Efgartigimod And ARGX-117
Jun 30Argenx to regain global rights to cusatuzumab from Janssen Pharmaceuticals
Jun 07Argenx raises ~$1B in global offering
Feb 03argenx to raise $750M in proposed global offering
Feb 01argenx on target to file efgartigimod applications in Japan and Europe
Jan 08argenx and Zai Lab collaborate for Efgartigimod in Greater China
Jan 06Argenx inks $98M deal to secure accelared review status for efgartigimod
Nov 23argenx (ARGX) Investor Presentation - Slideshow
Nov 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$12m | US$656k | -US$295m |
| Sep 30 2023 | n/a | n/a | -US$234m |
| Jun 30 2023 | n/a | n/a | -US$397m |
| Mar 31 2023 | n/a | n/a | -US$511m |
| Dec 31 2022 | US$8m | US$639k | -US$710m |
| Sep 30 2022 | n/a | n/a | -US$909m |
| Jun 30 2022 | n/a | n/a | -US$907m |
| Mar 31 2022 | n/a | n/a | -US$595m |
| Dec 31 2021 | US$7m | US$652k | -US$408m |
| Sep 30 2021 | n/a | n/a | -US$373m |
| Jun 30 2021 | n/a | n/a | -US$319m |
| Mar 31 2021 | n/a | n/a | -US$573m |
| Dec 31 2020 | US$9m | US$641k | -US$608m |
| Sep 30 2020 | n/a | n/a | -US$535m |
| Jun 30 2020 | n/a | n/a | -US$359m |
| Mar 31 2020 | n/a | n/a | -US$275m |
| Dec 31 2019 | US$7m | US$589k | -US$181m |
| Sep 30 2019 | n/a | n/a | -US$109m |
| Jun 30 2019 | n/a | n/a | -US$104m |
| Mar 31 2019 | n/a | n/a | -US$47m |
| Dec 31 2018 | US$5m | US$573k | -US$76m |
| Sep 30 2018 | n/a | n/a | -US$56m |
| Jun 30 2018 | n/a | n/a | -US$47m |
| Mar 31 2018 | n/a | n/a | -US$46m |
| Dec 31 2017 | US$4m | US$365k | -US$34m |
Compensation vs Market: Tim's total compensation ($USD11.94M) is about average for companies of similar size in the US market ($USD13.56M).
Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.
CEO
Tim Van Hauwermeiren (51 yo)
16.1yrs
Tenure
US$11,944,835
Compensation
Mr. Timothy Van Hauwermeiren, also known as Tim, MSc, EMBA, has been Independent Director at iTeos Therapeutics, Inc. since June 2018. Mr. Van Hauwermeiren has general management and business development e...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 16.1yrs | US$11.94m | 0.19% $ 42.8m | |
| Chief Financial Officer | 2.9yrs | US$4.76m | 0.0050% $ 1.2m | |
| Chief Operating Officer | 1.2yrs | US$7.65m | no data | |
| VP & Global Head of Technical Operations | 2.1yrs | no data | no data | |
| Chief Scientific Officer | 1.3yrs | no data | 0.00087% $ 201.2k | |
| VP and Global Head of Corporate Communications & Investor Relations | 2.1yrs | no data | no data | |
| General Counsel | 2.3yrs | no data | 0% $ 0 | |
| Vice President of Corporate Development & Strategy | 4.9yrs | no data | 0.0021% $ 478.8k | |
| Global Head of Human Resources | 5.4yrs | no data | no data | |
| Global Head of Quality | 4.3yrs | no data | 0.00050% $ 115.7k | |
| Chief Medical Officer | 2.1yrs | no data | 0.0027% $ 636.1k |
2.3yrs
Average Tenure
51yo
Average Age
Experienced Management: ARGX's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 9.8yrs | US$11.94m | 0.19% $ 42.8m | |
| Independent Vice-Chairman of the Board | 9yrs | US$482.23k | 0.00076% $ 175.8k | |
| Independent Chairman of the Board | 9.8yrs | US$660.33k | 0.00076% $ 175.8k | |
| Independent Non-Executive Director | 7.1yrs | US$476.82k | 0.00076% $ 175.8k | |
| Independent Non-Executive Director | 6yrs | US$482.23k | 0.00076% $ 175.8k | |
| Independent Non-Executive Director | 8.1yrs | US$471.41k | 0.00076% $ 175.8k | |
| Member of Board Advisors | no data | no data | 0.62% $ 143.9m | |
| Member of Board Advisors | no data | US$622.58k | no data | |
| Independent Non-Executive Director | 1.3yrs | US$635.65k | 0.00022% $ 50.9k | |
| Independent Non-Executive Director | 1.7yrs | US$365.24k | 0.00038% $ 87.9k | |
| Member of Board Advisors | 1.2yrs | US$656.08k | 0.0056% $ 1.3m | |
| Member of Board Advisors | no data | no data | no data |
7.1yrs
Average Tenure
62.5yo
Average Age
Experienced Board: ARGX's board of directors are considered experienced (7.1 years average tenure).